Since the discovery of thienamycin,1,2) many carbapenem derivatives have been synthesized and intensive studies on carbapenem antibiotics are continuing today.3) Two 1-H carbapenem antibiotics imipenem/cilastatin4, 5) In this study, our attention is focused on the quater- 
2-[1,1-dimethyl-2-(1-piperazinyl)carbonyl]pyrrolidinio-4-ylthio group or a (2S,4S)-2-(4-carbamoylmethyl-4-
methylhomopiperazinio-1-ylcarbonyl)pyrrolidin-4-ylthio group show a potent and well balanced antibacterial activity against Gram-positive and Gramnegative bacteria, including Pseudomonas aeruginosa and also show a high urinary recovery. In this paper, we describe the synthesis and structureactivity relationships of the above mentioned two types were purified by reverse phase column chromatography and then lyophilized. 
Biological Properties
The antimicrobial activities (MICs) of the type I and II carbapenems are shown in Table 1 Furthermore, the antibacterial activity of 1-H carbamethylcarbapenem 12c, was lower against Gram-negative bacteria, including P, aeruginosa than that of 12c. The urinary recoveries of 12b and 12c in mice after sc administration were 26% and 82%, respectively. The low urinary recovery of 12b was probably due to the degradation by DHP-I. Compared to 12c, the fluoroethyl carbapenem 12d which was modified at the 1 position of the pyrrolidine moiety showed a lower activity against the majority of Gram-positive and Gram-negative bacteria. The ethylaminocarbonyl and azetidinylcarbonyl compounds 12e and 12f exhibited higher activity against P. aeruginosa. The pyrrolidinylcarbonyl analogue 12g, however, showed a lower activity against P. aeruginosa than 12c. The piperazinylcarbonyl analogue 12h exhibited a well balanced and potent antibacterial The type II carbapenems differ from the type I carbapenems in having a quaternary ammonium moiety at the 2 position of the pyrrolidine ring. The dimethylhomopiperazinio compound 17a showed excellent activity against Gram-positive and Gram-negative bacteria, especially, MRSA and P. aeruginosa, but it was toxic in mice (LD50: <1500mg/kg). In order to find a low toxicity compound, a variety of substituted alkyl groups were introduced to the ammonium moiety. The carbamoylmethyl derivative 17b exhibited a low toxicity (LD50: >1500mg/kg) and a well balanced and potent antibacterial activity against Gram-positive and Gramnegative bacteria. In the comparison of 17b with 17a and the piperazinio analogue 17c, 17b had a higher activity against Gram-positive bacteria, especially, MRSA, and the urinary recovery of 17b (46%) was similar to that of 17a and 17c. The bis (carbamoylmethyl) and 2-hydroxyethyl derivatives 17d and 17f had a slightly lower activity against Gram-negative bacteria than did 17b. The carboxymethyl derivative, particularly diastereomer 17eA, exhibited the most potent anti-pseudomonal activity but had inferior activity against Gram-positive bacteria, including MRSA. 17g and 17h, carbapenems having a pyrrolidinio and an ammonio moiety, respectively, showed slightly lower activity against Grampositive bacteria, including MRSA, than 17b. In order to clarify the in vivo activity of the type I and II carbapenems, the protective effects of 12h and 17b against IR spectra were recorded on a Nicolet NIC FT-IR (5SXC) spectrometer. NMR spectra were determined on a Varian EM-360L (60MHz), Jeol GX-270 (270MHz) or GX-400 (400MHz) spectrometer using tetramethylsilane (TMS) as an internal or external standard and sodium 3-(trimethylsilyl)-propionate-d4 (TSP) as an internal standard. The mp was determined using a Yanagimoto micro-melting point apparatus and was not corrected. UV spectra were recorded on a Shimadzu UV-3100 spectrometer. Column chromatography was
To a solution of (R)-1-t-butoxycarbonyl-3-hydroxypyrrolidine 1 (25g) in THE (250ml) were added triethylamine (16.9ml) and methanesulfonyl chloride (9.4 ml) under ice-cooling, and then the mixture was stirred for 30 minutes. The mixture was then further stirred at and washed with water and brine. The EtOAc layer was dried (Na2SO4) and concentrated by evaporation under reduced pressure to give (R)-1-t-butoxycarbonyl-3-methanesulfonyloxypyrrolidine as a colorless oil (31g):
To a solution of 4-methoxybenzyl mercaptan (16.9ml) in DMF (200ml) was added sodium hydride (5.32g, 55% w/w dispersion in mineral oil) under ice-cooling and then the mixture was stirred at room temperature for 30 minutes. To this mixture was added a solution of (R)-1-t-butoxycarbonyl-3-methanesulfonyloxypyrrolidine (31g) in DMF (50ml) under ice-cooling and then the mixture was stirred under ice-cooling for 30 minutes and allowed to stand overnight at room temperature.
The mixture was poured into ice-water and extracted with EtOAc. The extract was washed with brine, dried (MgSO4), and concentrated by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (hexane-EtOAc, 5:1) to give was diluted with diisopropyl ether (200ml), and the crystals which precipitated from the mixture were filtered and dried to give (S)-3-(4-methoxybenzylthio) pyrrolidine
To a solution of (S)-3-(4-methoxybenzylthio) pyrrolidine (750mg) in acetonitrile (15ml), which was prepared by neutralization of (S)-3-(4-methoxybenzylthio) pyrrolidine hydrochloride (900mg) with NaHCO3, were added 35% formaldehyde (1.44ml) and sodium cyanoborohydride (338mg) at room temperature, and then the mixture was stirred for 15 minutes. To the mixture was added an excess amount of acetic acid and the mixture was then stirred at room temperature for 2. aq MeOH) to afford the title compound 12b as a colorless
To a solution of 6f (13.8g) in anisole were added TFA The mixture was concentrated by evaporation under reduced pressure, the residue was dissolved in THE (130ml) and water (100ml) and hydrogenated at room temperature for 3 hours in the presence of 10% Pdcharcoal (10g). The catalyst was removed from the reaction mixture by filtration with Celite and the filtrate was washed twice with diethyl ether. The aqueous layer was then concentrated by evaporation under reduced pressure. The residue was chromatographed through DOWEX 1-X4 (Cl-type) column developed with water. The desired fraction was concentrated and purified by a riverse phase column chromatography (nacalai tesque, Cosmosil 75C18-PREP, water) to afford the title compound 17b as a colorless powder (1.45g): were dissolved in water and then subcutaneously administered to mice (n=5, SPF ddY strain). Urine was collected at 8 hours and 24 hours after administration.
Excretion as the parent carbapenem was determined by bioassay using Bacillus subtilis ATCC 6633. Urinary excretion and the initial dose.
Therapeutic Effect on Systemic Mouse Infections
Trypto-soy broth (Eiken Chemical Co., Ltd., Tokyo, Japan) were diluted according to their virulence. The diluted cultures, if necessary, were mixed with the same amount of 5% gastric mucin (Tokyokasei-kogyo Co., Ltd., Tokyo, Japan). Seven male SPF ddY mice in each group were infected intraperitoneally with 0.2ml portions
